1A9bnbK

***
THE DISEASES − CHAPTER 4
119
Investment targets for active case-finding, vector control, and treatment
and care of visceral leishmaniasis (including medicines), 2015–2030
160
120
Constant US$ millions
80
40
0
2015
2020
Year
2025
2030
Notes: Grey lines represent uncertainty bands (5th and 95th centiles). The light blue section represents the
transition period from actual coverage reported in 2012; coverage data are not currently available for active case
finding or vector control.
Investment targets for treatment and care of cutaneous leishmaniasis
(including medicines), 2015–2030
●
20
Constant US$ millions
15
10
5
0
2015
2020
Year
2025
2030
Notes: Shaded areas reflect the range determined by low and high values of the unit cost benchmarks; they do
not reflect uncertainty about future rates of scale-up and scale-down of interventions. The dots in 2012 are actual
numbers reported (when available) multiplied by the unit cost benchmarks; these are not actual expenditures, but
can be thought of as a benchmark for actual expenditures. All numbers expressed in US$ are constant (real) US$,
adjusted to reflect purchasing power in the United States of America in 2015.
be. 10,11 The financial impact of cutaneous leishmaniasis to the health system is considerable.
Medical and non-medical costs associated with an outbreak exceeded US$ 385 000 for the
treatment of 1524 patients in a single hospital, excluding indirect costs incurred by those
patients (e.g. travel costs or loss of salaried work-time). 12 These costs would dramatically
decrease if a topical treatment based on paromomycin cream is proven as a convenient tool
for large-scale treatment of the most prevalent disease forms. 13,14